Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention

• Published in: Journal of thrombosis and thrombolysis 2001-05, Vol.11 (3), p.203-209
• Main Authors: KIMMELSTIEL, Carey, PHANG, Robert, REHMAN, Asif, RAND, William, MIELE, Regina, RHOFIRY, Joanne, MACISAAC, Debra A, GOUVEIA, William, DENIER, Donna, BECKER, Richard C
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary - adverse effects; Angioplasty, Balloon, Coronary - economics; Angioplasty, Balloon, Coronary - mortality; Antibodies, Monoclonal - administration & dosage; Biological and medical sciences; Creatine Kinase - blood; Diseases of the cardiovascular system; Drug Therapy, Combination; Female; Fibrinolytic Agents - administration & dosage; Hemorrhage - etiology; Heparin - administration & dosage; Humans; Immunoglobulin Fab Fragments - administration & dosage; Length of Stay; Male; Medical sciences; Middle Aged; Peptides - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - economics; Platelet Aggregation Inhibitors - therapeutic use; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors; Prospective Studies; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Tyrosine - administration & dosage; Tyrosine - analogs & derivatives
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1023/A:1011904718960

Platelet glycoprotein (GP) IIb/IIIa antagonists reduce the occurrence of death, myocardial infarction (MI) and urgent revascularization among patients undergoing percutaneous coronary intervention (PCI). Despite a similar mechanism of platelet inhibition, the three currently approved agents vary widely in cost. The purpose of this prospectively designed, retrospective analysis was to determine clinical outcomes for patients receiving abciximab, tirofiban or eptifibatide as adjunctive therapy during PCI at a single center. We hypothesized that there would be no difference in outcomes during hospitalization following PCI in patients receiving tirofiban or eptifibatide compared with those patients who received abciximab. Outcomes examined included in-hospital mortality, hemorrhagic procedural complications, need for recatheterization, peak creatine kinase following intervention and length of hospital stay (LOS). Two hundred and sixty seven consecutive patients in whom GP IIb/IIIa antagonist therapy was initiated in the catheterization laboratory for PCI were analyzed. Abciximab-treated patients were more likely to be undergoing primary (p